Day: October 7, 2021

HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) — Occidental (NYSE:OXY) will announce its third quarter 2021 financial results after close of market on Thursday, November 4, 2021, and will hold a conference call to discuss results on Friday, November 5, 2021, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at oxy.com/investors. Participants may pre-register for the conference call at https://dpregister.com/sreg/10160067/ed1794c606. Third quarter 2021 financial results will be available through the Investor Relations section of the company’s website. A recording of the webcast will be posted on the website within several hours after the call is completed. About Occidental Occidental is an international energy company with assets in...

Stage 2A expansion underway to increase annual throughput by +25% to 500,000 tonnes per annum (“tpa”) or 1,370 tonnes per day (“tpd”) from 400,000 tpa or 1,100 tpd. Performance of existing process plant has already shown the ball mill is capable of well above 400,000 tpa (1,100 tpd). Since Stage 2 Plant commissioning in 3Q 2020, the mill has consistently demonstrated an ability to deliver a notably finer than required product size, while also achieving up to 28% higher throughput with a single day record of 1,408 tonnes processed on September 22, 2021. Plant expansion involves low capital cost upgrades with an estimated capital cost of US$2.5 million and full commissioning to commence in 3Q 2022. Several expansion items have already arrived on site, and the expansion involves the following:Additional filter press on site and being commissioned.Additional...

TORONTO, Oct. 07, 2021 (GLOBE NEWSWIRE) — Artificial Intelligence company, AnalytixInsight Inc. (“AnalytixInsight”, or the “Company”) (TSX-V: ALY; OTCQB: ATIXF), announces that it will be presenting at the 2021 LD Micro Main Event MicroCap Investor Conference in Los Angeles on Tuesday, October 12, 2021 at 1:30PM PT (4:30PM ET), and will host one-on-one meetings with interested investors during the conference. During the presentation, the Company will discuss InvestoPro, its AI-assisted online trading platform that has been jointly introduced as the trading platform of one of the top banking groups in Europe. Conference registration for both in-person and virtual attendees is available here. The Company’s investor presentation is available here. LD Micro is the host of one of the most influential conferences in the small and microcap...

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights Data from ongoing Phase 2 trials in CF expected in 4Q 2021 WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that it will host an Investor and Analyst call and webcast on Tuesday, October 12, 2021. The event will include an update on the company’s cystic fibrosis programs and will feature Dr. Eitan Kerem, a globally renowned CF expert. The event is intended to provide insight into Eloxx’ CF programs, as data from the ongoing Phase 2 trials in CF are expected in the fourth quarter of 2021. Date: Tuesday, October 12, 2021Time: 10:00 a.m. ETDomestic Dial-in Number: (866) 913-8546International Dial-in Number: (210) 874-7715Conference ID: 8378144Live Webcast and Presentation Materials: accessible from the...

Conference Call to Discuss Results Scheduled for November 2nd, 2021 PARSIPPANY, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) — Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its third quarter 2021 results after the market close on Monday, November 1st, 2021, and to host a conference call for institutional investors to discuss these results on Tuesday, November 2nd, 2021 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to the call. A web replay will be available at ir.avisbudgetgroup.com following the call. A telephone replay will be available from 11:00 a.m. Eastern time on November 2nd, 2021 until 10:00 p.m. on November 16th, 2021 at (877)-660-6853 using conference code 13723926. About...

Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to Therapy Investigation Ongoing to Further Characterize the Finding, Including Any Clinical Relevance, Evidence of Clonal Expansion, or Potential Relationship to Gene Editing Company Believes Data from the ALPHA Trials Demonstrates a Favorable Clinical Profile of ALLO-501A FDA Continues to Review End of Phase 1 Materials for a Phase 2 Pivotal Trial of ALLO-501A Company to Host Conference Call Today at 2:00 p.m. PT/5:00 p.m. ETSOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today reported...

Gig Harbor, Washington,, Oct. 07, 2021 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (Nasdaq: HCDI, HCDIP, HCDIW, HCDIZ) (“Harbor,” “Harbor Custom Homes®,” or the “Company”), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced the closing of its previously announced underwritten public offering (the “Offering”) of 2,400,000 shares of 8.0% Series A Cumulative Convertible Preferred Stock (the “Series A Preferred Stock”) and 13,800,000 warrants to each purchase one share of common stock, including 1,800,000 warrants as a result of a partial exercise of the over-allotment option granted to the underwriter (“Warrants”). Harbor Custom Development, Inc. received gross proceeds of approximately $36.0 million from the Offering, prior to deducting underwriting discounts...

First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignancies Initial data from the NKX019 clinical trial expected in 2022 Initial data from Phase 1 clinical trial evaluating NKX101 in AML and MDS expected in 1H 2022SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced NKX019 and NKX101 clinical development program updates. Patients have been dosed in the international Phase 1 clinical trial of NKX019 in advanced B-cell malignancies. NKX019 is an NK cell immunotherapy that is engineered to eradicate tumors expressing CD19, a validated B-cell cancer target. “We are excited to explore the potential of NKX019, our second clinical-stage,...